Experimental radioactive Hodgkin's therapy shows promise in Phase I trial
Researchers are encouraged by the results of a small, Phase I experimental trial of a targeted, radioactive monoclonal antibody in patients with relapsed or refractory Hodgkin's lymphoma known as I-CHT25.
The small trial only involved a handful of patients, but according to results published in the journal Clinical Cancer Research, two thirds of patients had complete response to the therapy, in which cancer cells were exposed to radioactive isotopes for as many as four days without ostensible damage to surrounding tissue.
The experimental therapy appears to function similarly to Bexxar and Zevalin.
The study was backed by Cancer Research UK's Experimental Cancer Medicine Centre at University College London, and development of a Phase II trial for I-CHT25 is underway.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
